Abstracts side effects, which may be prevented with prophylactic prescription of misoprostol, omeprazole, or famotidine. Recently marketed COX-2 specific inhibitor (COX-2) affords protection against gastropathy. OBJECTIVE: To assess cost-effectiveness of NSAIDs vs COX-2 and NSAIDs with co-treatments to prevent GI toxicity in the treatment of RA. METHODS: Markov models were used to simulate a cohort of RA patients with approximately 2.5:1 female to male ratio and 50 years, taking disease modifying antirheumatic drugs and one of following strategies: NSAIDs without prophylaxis, COX-2, NSAIDs with misoprostol, omeprazole, or famotidine. Data on incidence, costs and consequences of adverse events from treatments were taken from the literature. Costs were measured in 1999 US dollars and health effects expressed as quality-adjusted life years (QALYs). Sensitivity analyses were performed. Costs and health outcomes were discounted at a rate of 3% per year. RESULTS: Among the strategies to prevent GI toxicity, COX-2 was the most cost-effective strategy and famotidine was the least costeffective strategy. The incremental C/E (cost/effectiveness) ratio between no prophylaxis and COX-2 is 62,278 ($/QALY). Sensitivity analyses using incidence rates were robust. CONCLUSIONS: COX-2 is the best option among the strategies to prevent GI toxicity. However, the incremental C/E between no prophylaxis and COX-2 strategies is over 60,000 ($/QALY). 
OBJECTIVE:
To compare the total costs associated with two different anti-TNF agents used in the treatment of moderate to severe rheumatoid arthritis: etanercept, which can be administered at home by a subcutaneous injection, versus infliximab, which requires an intravenous infusion in day-care. METHODS: An economic model was constructed to determine the costs of both treatments. The cost 
To evaluate the total resource consumption and the costs for diagnostics and treatments per patient with severe chronic polyarthritis (cp) from the third party payers' (TPP) perspective in Germany. METH-ODS: A retrospective cross-sectional cost of illness-study was performed. Patients (18 to 75 years) with acute disease activity of cp with a history of therapy failure with MTX over a minimum of 4 months or failure of more than one basic treatment were included. Hospital and practice data was abstracted from patient's records. Statistical analysis and cost evaluation were performed by using the SAS package. Cost data was taken from published German tariff and price lists. RESULTS: The mean age of the patients was 56 years, 71.2% were females. The mean onset of the disease was 11.2 years ago. The total average costs of outpatient care (n ϭ 191 patients) were approximately 3,445 DM (95% CI: 2,981-3,907 DM) and for inpatient care (n ϭ 76 patients) 10,433 DM (95% CI: 8,800-12,067 DM) per year. Concerning outpatient care drug therapy could be identified as the most relevant cost driver (69% of the total costs) followed by diagnostic procedures (10%). The duration of the stay in hospital is the decisive factor for the costs of inpatient care from TPP's perspective in Germany. The average hospitalization length was 19.5 days. Assuming a hospitalization rate of 10% the direct medical costs per cp patient and year were 4,488 DM. CONCLUSION: It could be shown that treatment of chronic polyarthritis is as cost-intensive as other chronic diseases. Because of the growing interest in the development of new concepts of patient care (e.g. disease management), further cost and outcome data should be assessed to show the relative value for money (e.g. with cost-effectiveness analysis) in order to guarantee an appropriate allocation of resources. -II inhibitors (celecoxib, etodolac, meloxicam and rofecoxib) and 'best-practice' guidelines in the treatment of arthritis was undertaken. The review concentrated on the problems of NSAID-related GI adverse events, their associated treatment costs and whether COX-II inhibitors provide alternative, clinically and cost-effective methods of treating arthritis. RESULTS: NSAID-related GI risk rises significantly with patient age. In the UK, NSAID-related deaths average 2,600 patients annually. The mean, NHS cost of NSAID-related, GI adverse events is an extra £48 per NSAID patient per year. COX-II specifics have significantly better GI tolerability to NSAIDs. But COX-II specifics cost the NHS an extra £40.15 minimum annually for the average NSAID patient. COX-II selectives are cheaper than COX-II specifics and have significantly higher GI tolerability than NSAIDs. CONCLUSIONS: COX-II inhibitors represent a more clinically effective solution for treating arthritis and reducing GI adverse events in primary care than NSAIDs. There is a lack of 'real-life evidence' to determine for which at risk patients COX-II specifics are cost-effective over the COX-II selectives and NSAIDs. Best-practice guidelines support the view that there is a role for COX-II specifics, COX-II selectives and NSAIDs in treating arthritis in primary care.
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COX-II INHIBITORS AND NSAIDS: FINDINGS OF A NICE SUBMISSION
